Navigation Links
Perrigo Acquires Rights to Generic Version of HalfLytely® from Novel Laboratories
Date:5/26/2010

ducts for the store brand market. The Company's primary markets and locations of manufacturing and logistics operations are the United States, Australia, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (http://www.perrigo.com).

Note: Certain statements in this press release are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby. These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the y
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Company to Present at the Citi Investment Research Global Health Care Conference
2. Perrigo Company Announces Quarterly Dividend
3. Perrigo Acquires Infant Formula Manufacturer PBM Holdings for $808 Million
4. Perrigo Company Announces Quarterly Dividend
5. Perrigo Company Will Release Second Quarter Fiscal 2010 Results on February 2, 2010
6. Perrigo Company to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix
8. Perrigo Company To Present at the Sidoti Emerging Growth Conference
9. Perrigo Company Announces Dividend Increase
10. Perrigo Company Will Release First Quarter Fiscal 2010 Results on November 2, 2009
11. Perrigo Confirms Filing for Generic Version of Mens Rogaine(R) Foam
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 2014 Los beneficios y ganancias ... nivel de gasto en investigación y desarrollo   ... 30 de septiembre de 2014) ZEISS aumentó sus ingresos ... euros (año anterior: 4.190 millones de euros) a pesar ... (EBIT) crecieron un 14 por ciento, a 360 millones ...
(Date:12/17/2014)... HOLBROOK, N.Y. , Dec. 17, 2014 /PRNewswire/ ... that The Depository Trust Company (DTC) has made ... the Deposit Chill on the Company,s stock effective ... of Northstar,s common stock for depository and book ... and the Company is now once again fully ...
(Date:12/17/2014)... MILAN , December 17, 2014 ... becoming nothing less than a hub of information concerning the ... A further addition to the recently launched ... world and has now been enriched by a new chapter ... A richly detailed and panoramic hub on ...
Breaking Medicine Technology:ZEISS confirma su posición en un entorno difícil 2Northstar announces that the DTC chill on MDIN has been officially lifted 2Northstar announces that the DTC chill on MDIN has been officially lifted 3Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 2Dompé Offers a New "Window" on the World of Scientific Research, with the http://www.dompetrials.com Website, Dedicated to Clinical Trials 3
... - GenVec, Inc.,(Nasdaq:GNVC) announced today data from ... of the American Association of Cancer,Research (AACR) ... systems,to deliver the gene for tumor necrosis ... (TNFerade),is an adenovector, or DNA carrier, which ...
... 2007 /PRNewswire-FirstCall/ --,Telik, Inc. announced the presentation ... trial of the triplet combination of TELCYTA(R),(canfosfamide ... treatment of advanced non-small cell lung cancer. ... in both progression-free survival and overall survival,in ...
Cached Medicine Technology:GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 2GenVec Announces New Research at AACR on Selectivity and Mechanism,of Action of TNF-Based Anti-Cancer Therapy 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 2Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 3Telik Reports Positive Data Demonstrating Synergy in Combination,and Highly Statistically Significant Effect of Telcyta as,Maintenance Therapy in First-Line Non-Small Cell Lung Cancer 4
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... The increase in prevalence of disabling hearing loss ... which is contributing to the growth in the global audiological ... of hearing loss and balance disorders are known as audiological ... speaker and amplifier. The global market is expected to grow ... period from 2014 to 2019. Some of the factors which ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 Emergo Group, ... in 26 countries in North and South America, Europe, ... responses from industry participants for its 2015 Medical Device ... order to identify upcoming business and market trends as ... , The survey targets areas including:, , ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 At the ... organizations AutismOne and Focus Autism ... attendees with research on the effects of toxins to ... and intervention information. , Luminaries such as Dr. ... from abroad with esteemed, credentialed colleagues of the United ...
(Date:12/15/2014)... 2014 Kenmode Precision Metal Stamping has ... Director of Quality Assurance. He brings more than ... and certifications for manufacturers in the U.S. and abroad. ... Quality Manager at Sonoco Products Company in the Protective ... and Quality Assurance Manager for Prince Industries, all in ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... vaccine is the first 5-in-1 pediatric combination for, immunization against ... ... b (Hib) -, SWIFTWATER, Pa. and LYON, France, June ... announced today,that the U.S. Food and Drug Administration (FDA) has ...
... AM ET MONDAY JUNE 23, 2008 , LOW SOCIOECONOMIC ... Cancer patients with low socioeconomic status (SES) have more advanced ... higher risk of dying in the five years following cancer ... appear in the August 1, 2008 issue of CANCER ...
... can prevent unnecessary accidents, experts say , , SUNDAY, June ... can greatly reduce the risk of serious head, spinal ... and recreational activities, says the American Association of Neurological ... head injuries treated in U.S. hospital emergency rooms in ...
... under 80, could ease expected worldwide shortfall of supplies , , ... called HBOC-201 proved safe and effective in a six-week Phase ... In all, 688 patients, ages 18 and older, who had ... (about one pint) or an equivalent one unit (65 grams) ...
... earlier treatment options for patients -, ... Millennium,Pharmaceuticals, The Takeda Oncology Company, and ... announced that the U.S. Food,and Drug Administration ... multiple myeloma (MM). The Company,s co-development partner,Johnson ...
... SAN FRANCISCO, June 20 The San Francisco,Medical Society ... in,Medical/Health Reporting." This $1,000 award is presented each ... good work of California reporters,from television, radio and ... 30, 2008 for the 2009 award., A ...
Cached Medicine News:Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 2Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 3Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 4Health News:U.S. FDA Licenses Sanofi Pasteur's New Pediatric Combination Vaccine, Pentacel(R) 5Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 2Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 3Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 4Health News:Risk of death after cancer diagnosis; shift in stage of breast cancer diagnosis 5Health News:Head Injuries All Too Common in Summer Play 2Health News:Blood Substitute Found Safe in Large Phase III Trial 2Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 2Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 3Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 4Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 5Health News:FDA Approves VELCADE(R) (Bortezomib) for Injection for Patients with Previously Untreated Multiple Myeloma 6Health News:SFMS David Perlman Award For Excellence in Medical/Health Reporting Recognizes Local Reporters 2
... The Cholestech LDX System, using patented, innovative ... glucose and ALT in only 5 minutes ... ALT test, you can get immediate liver ... capabilities is not the only advantage to ...
The Strep A Rapid Test Strip is a rapid chromatographic,immunoassay for the qualitative detection of Strep A antigen,from throat swab specimens to aid in the diagnosis of Group A,Streptococcal ...
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
Medicine Products: